Michael K. Lee

发表

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice

Weiming Xia, Paul Fraser, J. Rommens, 1997, Nature Medicine.

Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies

R. Black, K. Johnson-wood, P. Seubert, 2005 .

Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease*

R. Barbour, P. Seubert, D. Schenk, 2006, Journal of Biological Chemistry.

Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

Makoto Hashimoto, Michael Alford, E. Masliah, 2005, Neuron.

Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice*

Manuel Buttini, R. Motter, K. Johnson-wood, 2007, Journal of Biological Chemistry.

Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease

R. Motter, R. Barbour, K. Johnson-wood, 1997 .

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

E. Masliah, E. Rockenstein, P. Seubert, 2005, Neuron.

Cell-type and Amyloid Precursor Protein-type Specific Inhibition of Aβ Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases (*)

L. McConlogue, P. Seubert, S. Sinha, 1995, The Journal of Biological Chemistry.

Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

D. Selkoe, R. Wolfert, C. Vigo‐Pelfrey, 1992, Nature.

Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.

G. Schellenberg, T. Montine, V. Lee, 2006, Journal of Alzheimer's disease : JAD.

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

R. Black, K. Johnson-wood, P. Seubert, 2005, Annals of neurology.

Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration

R. Motter, D. Kholodenko, K. Hu, 2010, Alzheimer's & Dementia.

Erratum: Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology (Proceedings of the National Academy of Science of the United States of America (February 18, 2003) 100, 4 (2023-2028))

R. Motter, D. Kholodenko, R. Barbour, 2004 .

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.